

*Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited (the “**Hong Kong Stock Exchange**”) and Hong Kong Securities Clearing Company Limited (“**HKSCC**”) take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

*This announcement is not for release, publication or distribution, directly or indirectly, in or into the United States (including its territories and possessions, any state of the United States and the District of Columbia). This announcement does not constitute or form a part of any offer or solicitation to purchase or subscribe for securities in the United States. The Offer Shares have not been and will not be registered under the U.S. Securities Act or any state securities law in the United States and may not be offered, sold, pledged or transferred within the United States, except that Offer Shares may be offered, sold or delivered to QIBs in reliance on an exemption from registration under the U.S. Securities Act provided by, and in accordance with the restrictions of, Rule 144A or another exemption from the registration requirements of the U.S. Securities Act. The Offer Shares may be offered, sold or delivered outside the United States in offshore transactions in accordance with Regulation S.*

*Unless otherwise defined herein, capitalised terms in this announcement shall have the same meanings as those defined in the prospectus dated 1 March 2016 (the “**Prospectus**”) issued by Union Medical Healthcare Limited (the “**Company**”).*

*This announcement is for information purposes only and does not constitute an offer or an invitation to induce an offer by any person to acquire, purchase or subscribe for securities of the Company. This announcement is not a prospectus. Potential investors should read the Prospectus for detailed information about the Hong Kong Public Offering and the International Offering described below before deciding whether or not to invest in the Offer Shares thereby being offered.*



## **Union Medical Healthcare Limited**

**香港醫思醫療集團有限公司\***

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 2138)**

### **STABILISING ACTIONS AND END OF STABILISATION PERIOD**

The Company announces that the stabilisation period in connection with the Global Offering ended on 3 April 2016, being the 30th day after the last day for the lodging of applications under the Hong Kong Public Offering.

The Company was informed by Credit Suisse (Hong Kong) Limited, the Stabilising Manager, that the stabilising actions undertaken by Credit Suisse (Hong Kong) Limited, its affiliates or any person acting for it during the stabilisation period were:

- (i) over-allocation of an aggregate of 36,500,000 Shares in the International Offering, representing approximately 15% of the Offer Shares initially offered under the Global Offering before any exercise of the Over-allotment Option;
- (ii) the borrowing of an aggregate of 36,500,000 Shares from Union Medical Care pursuant to the Stock Borrowing Agreement to cover the over-allocations in the International Offering;
- (iii) successive purchases of an aggregate of 35,673,000 Shares in the price range of HK\$2.82 to HK\$3.03 per Share (exclusive of brokerage of 1%, SFC transaction levy of 0.0027% and Hong Kong Stock Exchange trading fee of 0.005%) on the market during the stabilisation period. The last purchase made by the Stabilising Manager on the market during the course of the stabilisation period was on 1 April 2016 at the price of HK\$2.9335 per Share (exclusive of brokerage of 1%, SFC transaction levy of 0.0027% and Hong Kong Stock Exchange trading fee of 0.005%); and
- (iv) the partial exercise of the Over-allotment Option by the Sole Global Coordinator, on behalf of the International Purchasers, on 1 April 2016 in respect of an aggregate of 827,000 Shares, representing approximately 0.34% of the total number of Offer Shares initially available under the Global Offering before any exercise of the Over-allotment Option, at the Offer Price per Share.

## **STABILISING ACTIONS AND END OF STABILISATION PERIOD**

The Company announces that the stabilisation period in connection with the Global Offering ended on 3 April 2016, being the 30th day after the last day for the lodging of applications under the Hong Kong Public Offering.

The Company was informed by Credit Suisse (Hong Kong) Limited, the Stabilising Manager, that the stabilising actions undertaken by Credit Suisse (Hong Kong) Limited, its affiliates or any person acting for it during the stabilisation period were:

- (i) over-allocation of an aggregate of 36,500,000 Shares in the International Offering, representing approximately 15% of the Offer Shares initially offered under the Global Offering before any exercise of the Over-allotment Option;

- (ii) the borrowing of an aggregate of 36,500,000 Shares from Union Medical Care pursuant to the Stock Borrowing Agreement to cover the over-allocations in the International Offering;
- (iii) successive purchases of an aggregate of 35,673,000 Shares in the price range of HK\$2.82 to HK\$3.03 per Share (exclusive of brokerage of 1%, SFC transaction levy of 0.0027% and Hong Kong Stock Exchange trading fee of 0.005%) on the market during the stabilisation period. The last purchase made by the Stabilising Manager on the market during the course of the stabilisation period was on 1 April 2016 at the price of HK\$2.9335 per Share (exclusive of brokerage of 1%, SFC transaction levy of 0.0027% and Hong Kong Stock Exchange trading fee of 0.005%); and
- (iv) the partial exercise of the Over-allotment Option by the Sole Global Coordinator, on behalf of the International Purchasers, on 1 April 2016 in respect of an aggregate of 827,000 Shares, representing approximately 0.34% of the total number of Offer Shares initially available under the Global Offering before any exercise of the Over-allotment Option, at the Offer Price per Share, to cover over-allocations in the International Offering. The over-allotment Shares were allotted and issued by the Company at HK\$3.03 per Share (exclusive of brokerage of 1%, SFC transaction levy of 0.0027% and Hong Kong Stock Exchange trading fee of 0.005%), being the Offer Price per Share under the Global Offering.

For further details of the partial exercise of the Over-allotment Option, please refer to the announcement of the Company dated 1 April 2016.

On behalf of the Board  
**Union Medical Healthcare Limited**  
**Mr. Tang Chi Fai**  
*Chairman*

Hong Kong, 4 April 2016

*As at the date of this announcement, the board of Directors comprises Mr. Tang Chi Fai, Mr. Lee Gabriel, Mr. Luk Kun Shing Ben and Mr. Yeung Chin Wan as executive Directors, and Mr. Ma Ching Nam, Mr. Yu Ka Fai Alexis and Mr. Look Andrew as independent non-executive Directors.*